Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2024-05-14 00:00:00 ET · period of report 2024-05-13 · accession 0001562180-24-004025 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2024-05-14 | 2024-05-13 | AKBA | Dahan Michel | SVP, COO | S - Sale | $1.26 | -34.8K | 672.1K | -5% | -$43.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-13 | S | D | 34,840 | $1.26 | 672,092 | D | — | — | (F1) This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023. (F2) This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2023. |